Classification of systemic sclerosis in the Japanese population based on rapid progression of skin thickening

Modern Rheumatology

Volumn 14, Issue 3, 2004, Pages 216-221

  Nishimagi, Emi ^a   Kawaguchi, Yasushi ^a   Tanaka, Eiichi ^a   Hara, Masako ^a   Kamatani, Naoyuki ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Classification; Systemic sclerosis (SSc); Total skin score

Indexed keywords

ANTINUCLEAR ANTIBODY; CENTROMERE ANTIBODY; DNA TOPOISOMERASE; ENZYME ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; IMMUNODIFFUSION; IMMUNOFLUORESCENCE; INTERSTITIAL LUNG DISEASE; JAPAN; KIDNEY DISEASE; LABORATORY DIAGNOSIS; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; SCLERODERMA; SCORING SYSTEM; SKINFOLD THICKNESS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTEMIC SCLEROSIS;

EID: 4444277192     PISSN: 14397595     EISSN: None     Source Type: Journal    
DOI: 10.3109/s10165-004-0294-5     Document Type: Article

References (26)

1. Medsger TA Jr. Systemic sclerosis (scleroderma): clinical aspects. In: Koopman WJ, editor. Arthritis and allied conditions. 14th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 1590-624.
2. Bennett R, Bluestone R, Holt PJ, Bywaters FG. Survival in scleroderma. Ann Rheum Dis 1971;30:581-8.
3. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification subsets and pathogenesis. J Rheumatol 1988;15:202-5.
4. Medsger TA Jr, Masi AT, Rodnan GP, Benedek TG, Robinson H. Survival with systemic sclerosis (scleroderma): a life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971;75:369-76.
5. Medsger TA Jr. Scleroderma: recent advances in the treatment of progressive systemic sclerosis. Orthop Rev 1984;13:69-80.
6. Steen VD, Medsger TA Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001;44:2828-35.
7. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
8. Clements PJ, Lachenbruch P, Seibold JR, White B, Weiner S, Martin RW, et al. Inter- and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
9. Clements PJ, Lachenbruch PA, Swee Chen NG, Simmons M, Sterz M, Furst DE. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in system sclerosis. Arthritis Rheum 1990;33:1256-63.
10. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;11:2437-44.
11. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;9:1283-9.
12. Bryan C, Knight C, Black CM, Silman AJ. Prediction of five-year survival following presentation with scleroderma. Arthritis Rheum 1999;12:2660-5.
13. Diot E, Giraudeau B, Diot P, Degenne D, Ritz L, Guilmot JL, et al. Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis? Chest 1999;116:715-20.
14. Kuwana M, Kaburaki J, Mimori T, Kawakami Y, Tojo T. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 2000;43:1074-84.
15. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, et al. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993;36:340-7.
16. Fujimoto M, Shimozuma M, Yazawa N, Kubo M, Ihn H, Sato S, et al. Prevalence and clinical relevance of 52-kDa and 60-kDa Ro/SSA autoantibodies in Japanese patients with systemic sclerosis. Ann Rheum Dis 1997;56:667-70.
17. Frank MB, McCubbin V, Trieu E, Wu Y, Isenberg DA, Targoff IN. The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. J Autoimmun 1999;12:137-42.
18. Kuwana M, Kaburaki J, Arnett FC, Howard RF, Medsger TA, Wright TM. Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisonerase I antibody. Arthritis Rheum 1999;42:465-74.
19. Muhlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995;24:323-58.
20. Steen VD. Epidemiology of rheumatic disease: systemic sclerosis. Rheum Dis Clin North Am 1990;16:641-54.
21. Lee P, Langevitz P, Alderdize CA, Aubrey M, Baer PA, Baron M, et al. Mortality in systemic sclerosis (scleroderma). QJM 1992; 298:139-48.
22. Steen VD, Lanz JK Jr, Conte C, Owens GR, Medsger TA Jr. Therapy for interstitial lung disease in systemic sclerosis. Arthritis Rheum 1994;9:1290-6.
23. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000;132:947-54.
24. Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Conforti ML, et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002;29:731-6.
25. Pakas I, Ioannidis JPA, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG. Cyclophosphamide with low-or high-dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002;29:298-304.
26. McSweeney PA, Nash RA, Sullivan KM, Storek J, Dansey R, Mayes MD, et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 2002;100:1602-10.